SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Agnieszka Gunia-Krzyżak, Katarzyna Pańczyk, Anna M. Waszkielewicz, Henryk Marona, Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders—A Review of Structure–Activity Relationships, ChemMedChem, 2015, 10, 8
  2. 2
    Fatemeh Hemmati, Rasoul Ghasemi, Norlinah Mohamed Ibrahim, Leila Dargahi, Zahurin Mohamed, Azman Ali Raymond, Abolhassan Ahmadiani, Crosstalk Between Insulin and Toll-like Receptor Signaling Pathways in the Central Nervous system, Molecular Neurobiology, 2014, 50, 3, 797

    CrossRef

  3. 3
    Pierre-Olivier Fernagut, Benjamin Dehay, Aline Maillard, Erwan Bezard, Paul Perez, Anne Pavy-Le Traon, Olivier Rascol, Alexandra Foubert-Samier, François Tison, Wassilios G. Meissner, Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies, Neurobiology of Disease, 2014, 67, 133

    CrossRef

  4. 4
    Rasoul Ghasemi, Leila Dargahi, Ali Haeri, Maryam Moosavi, Zahurin Mohamed, Abolhassan Ahmadiani, Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders, Molecular Neurobiology, 2013, 47, 3, 1045

    CrossRef

  5. 5
    Lucas M. Chaible, Denise Kinoshita, Marcus A. Finzi Corat, Maria L. Zaidan Dagli, Animal Models for the Study of Human Disease, 2013,

    CrossRef

  6. 6
    Marie-Hélène Canron, Martine Perret, Anne Vital, Erwan Bézard, Benjamin Dehay, Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate, Scientific Reports, 2012, 2,

    CrossRef

  7. 7
    Brit Mollenhauer, Jing Zhang, Biochemical premotor biomarkers for Parkinson's disease, Movement Disorders, 2012, 27, 5
  8. 8
    Nadine Y. Lettfuss, Kristina Fischer, Vesna Sossi, Bernd J. Pichler, Andreas von Ameln-Mayerhofer, Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA, NeuroImage, 2012, 63, 1, 423

    CrossRef

  9. 9
    Kurt A. Jellinger, Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts, Movement Disorders, 2012, 27, 1
  10. 10
    Werner J Geldenhuys, David D Allen, Jeffrey R Bloomquist, Novel models for assessing blood–brain barrier drug permeation, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 6, 647

    CrossRef

  11. 11
    Patricia Muñoz, Sandro Huenchuguala, Irmgard Paris, Carlos Cuevas, Monica Villa, Pablo Caviedes, Juan Segura-Aguilar, Yousef Tizabi, Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease, Neurotoxicity Research, 2012, 22, 2, 177

    CrossRef

  12. 12
    Kurt Jellinger, The role of α-synuclein in neurodegeneration — An update, Translational Neuroscience, 2012, 3, 2

    CrossRef

  13. 13
    Alberto J Espay, Alfonso Fasano, Francesca Morgante, The six gaps in the search of neuroprotection for Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 2, 111

    CrossRef

  14. 14
    Trevor Tyson, Patrik Brundin, VPS41-mediated neuroprotection in aCaenorhabditis elegansmodel of Parkinson’s disease, Future Neurology, 2012, 7, 3, 255

    CrossRef

  15. 15
    Mariah J. Lelos, Eilís Dowd, Stephen B. Dunnett, Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I, 2012,

    CrossRef